Drugs / Galactose
Galactose
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00816504 | Dec 2008 → Dec 2009 | focal segmental glomerulosclerosis | Northwell Health | Withdrawn | No outcome recorded |
| Phase 1 | NCT00816478 | Dec 2008 → Dec 2009 | focal segmental glomerulosclerosis | Northwell Health | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04546022 | Jul → Aug 2007 | — | National Defense Medical Center, Taiwan | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05402384 | Jan 2027 → Mar 2028 expected | SLC35A2-congenital disorder of glycosylation | Eva Morava-Kozicz | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05402332 | Oct 2026 → Mar 2028 expected | PGM1-congenital disorder of glycosylation | Eva Morava-Kozicz | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00814255 | Dec 2008 → Jun 2013 | focal segmental glomerulosclerosis | NYU Langone Health | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03457311 | Sep 2013 → Mar 2018 | — | Richever Enterprise Co., Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01882218 | Sep 2012 → May 2014 | liver cancer | University of Louisville | Withdrawn | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT02702765 | Feb 2016 → Feb 2020 | Wilson disease | University of Aarhus | Completed | No outcome recorded |
| — | NCT01113385 | Oct 2009 → Mar 2013 | focal segmental glomerulosclerosis, steroid-resistant nephrotic syndrome | Children's National Research Institute | Completed | No outcome recorded |
| — | NCT00427986 | Jan → Mar 2007 | diabetic macular edema | Glostrup University Hospital, Copenhagen | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galactose | “subjects will be Intravenous administered with 1.25 ml/kg G.S.P. solution (400 mg/ml of galactose) to subjects after I.V. G.SP. solution within 3 to 5 minutes” NCT04546022 ↗7“400 mg/ml of galactose” NCT03457311 ↗ |
| Known as | AVTX-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05402384 ↗ |
| Known as | D-Galactose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01113385 ↗ |
| Action | Inhibit | “galactose, a simple milk sugar thought to bind to the protein factor (FSPF) that causes FSGS thereby inactivating it and stopping it from damaging the kidney” NCT01113385 ↗ |
| Modality | Small molecule | “a simple milk sugar” NCT01113385 ↗ |
| Route | Intravenous | “treatment with intravenous galactose can reduce the retinal thickness in diabetic macular oedema evaluated by OCT during a three-hour monitoring.” NCT00427986 ↗ |